Progressing DeNovaMed’s New CEO
With a new CEO in place, DeNovaMed Inc. believes it is enticingly close to identifying the single molecule it needs to proceed down the path to commercialization.
The Halifax biotech company drew local attention last year when it won Innovacorp’s I-3 competition on the strength of its development of new compounds that could treat infections caused by drug-resistant bacteria, or superbugs. The team has since worked on developing its drug while looking for a CEO, which it recently found in London, Ont., biotech exec Kevin Sullivan.
“We need to pick a lead molecule that we’re going to